LY4086940 Clinical Trials (2026): 1 Studies for Healthy & Obesity
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 LY4086940 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Healthy & Obesity) and 216 total planned enrollment. 1 LY4086940 clinical trial is actively recruiting at 1 U.S. site across 1 state. Most recent activity: NCT06945419 (Jul 2026).
Where to Participate: All LY4086940 Trial Sites in the U.S. (1 site across 1 state)
Every actively recruiting LY4086940trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| FL | Clinical Pharmacology of Miami | Miami33172 | NCT06945419 | Map |
LY4086940 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1 | 1 | 1 |
Recruiting LY4086940 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06945419 | A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes | P1 | Healthy | 216 | Apr 2025 |
All LY4086940 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06945419 | A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes | P1 | recruiting | 216 | Eli Lilly and Company | Apr 2025 |
LY4086940 clinical trials: frequently asked questions
- How many LY4086940 clinical trials are there?
- 1 LY4086940 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are LY4086940 clinical trials recruiting in 2026?
- Yes — 1 LY4086940 trial is actively recruiting in 2026, with 1 U.S. site across 1 state. See the recruiting trials and the per-state site list further down this page.
- What conditions is LY4086940 being studied for?
- LY4086940 is being studied for Healthy, Obesity, Overweight, Type 2 Diabetes. The trials are grouped by indication on this page.
- What phase is LY4086940 in?
- LY4086940 clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors LY4086940 clinical trials?
- The lead sponsor across the most LY4086940 trials is Eli Lilly and Company. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming LY4086940as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: